Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients (n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group (SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P = .015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P = .013, .042, and .0012) were associated with a poor EFS.

[1]  E. Kimby.  Serum cytokines in follicular lymphoma. , 2015, Blood.

[2]  A. LaCroix,et al.  Cytokines in serum in relation to future non‐Hodgkin lymphoma risk: Evidence for associations by histologic subtype , 2014, International journal of cancer.

[3]  K. Takata,et al.  Elevated soluble IL-2 receptor levels correlate with tumor bulk of follicular lymphomas with intestinal involvement. , 2014, Clinical biochemistry.

[4]  E. Carvalho,et al.  Soluble IL‐2 receptor and beta‐2 microglobulin as possible serologic markers of neurologic disease in HTLV‐1 infection , 2014, Journal of medical virology.

[5]  J. Cerhan,et al.  Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma , 2013, Clinical Cancer Research.

[6]  J. Cerhan,et al.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Arima,et al.  IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome , 2013, Annals of Hematology.

[8]  N. Rothman,et al.  A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. , 2013, Blood.

[9]  Summer S. Han,et al.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.

[10]  T. Yoshizato,et al.  Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. , 2013, Clinical lymphoma, myeloma & leukemia.

[11]  D. LeBrun,et al.  Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease , 2013, Leukemia & lymphoma.

[12]  Ash A. Alizadeh,et al.  High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. , 2013, Blood.

[13]  M. Kaminski,et al.  Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Henderson,et al.  Non-Hodgkin Lymphoma and Circulating Markers of Inflammation and Adiposity in a Nested Case–Control Study: The Multiethnic Cohort , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[15]  J. Cerhan,et al.  Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. , 2012, Cytokine.

[16]  K. Tarte,et al.  Stromal Cell Contribution to Human Follicular Lymphoma Pathogenesis , 2012, Front. Immun..

[17]  J. Cerhan,et al.  Elevated pretreatment serum levels of interferon‐inducible protein‐10 (CXCL10) predict disease relapse and prognosis in diffuse large B‐cell lymphoma patients , 2012, American journal of hematology.

[18]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[19]  J. Byrd,et al.  A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders , 2012, Clinical Cancer Research.

[20]  T. Niki,et al.  IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[21]  S. Ansell,et al.  Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. , 2011, Blood.

[22]  P. Allavena,et al.  Chemokines in cancer related inflammation. , 2011, Experimental cell research.

[23]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[24]  C. Doglioni,et al.  Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T‐cell infiltration and positioning of malignant B cells , 2010, International journal of cancer.

[25]  P. Vineis,et al.  Plasma Cytokines and Future Risk of Non-Hodgkin Lymphoma (NHL): A Case-Control Study Nested in the Italian European Prospective Investigation into Cancer and Nutrition , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[26]  S. Zupo,et al.  Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. , 2010, Experimental hematology.

[27]  J. D. Vos,et al.  Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis , 2009, Leukemia.

[28]  E. Jaffe,et al.  IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. , 2008, Blood.

[29]  Tracy M Handel,et al.  Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. , 2008, The Biochemical journal.

[30]  S. Akira,et al.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. , 2007, The Journal of clinical investigation.

[31]  A. Alves,et al.  Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients? , 2007, Leukemia & lymphoma.

[32]  M. Caligiuri,et al.  A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[33]  S. Ansell,et al.  Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients , 2006, Clinical Cancer Research.

[34]  Nilanjan Chatterjee,et al.  Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. , 2006, Cancer research.

[35]  E. Giné,et al.  The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  R. Fisher,et al.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Hwang,et al.  Chemokines, chemokine receptors, and cancer metastasis , 2006, Journal of leukocyte biology.

[38]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[39]  E. Giné,et al.  Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients , 2006, European journal of haematology.

[40]  I. Soubeyran,et al.  Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome , 2006, Leukemia & lymphoma.

[41]  J. Briones,et al.  Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Solal-Céligny.  Prognosis of follicular lymphomas. , 2005, Clinical lymphoma.

[44]  A. Hagenbeek,et al.  Meta-analysis to evaluate the role of interferon in follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Lister,et al.  The clinical course of follicular lymphoma. , 2005, Best practice & research. Clinical haematology.

[46]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[47]  A. López-Guillermo,et al.  Follicular lymphoma international prognostic index. , 2004, Blood.

[48]  Santa Jeremy Ono,et al.  Chemokines: roles in leukocyte development, trafficking, and effector function. , 2003, The Journal of allergy and clinical immunology.

[49]  K. Karube,et al.  Expression of Chemokine Receptor CXCR3 and its Ligand, Mig, in Gastric and Thyroid Marginal Zone Lymphomas. Possible Migration and Autocrine Mechanism , 2003, Leukemia & lymphoma.

[50]  H. Joensuu,et al.  Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.

[51]  K. Park,et al.  Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. , 1999, Journal of dermatological science.

[52]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[53]  P. Galieni,et al.  Detection of soluble interleukin‐2 receptor and interleukin‐10 in the serum of patients with aggressive non‐Hodgkin's lymphoma.Identification of a subset at high risk of treatment failure , 1994, Cancer.

[54]  G. Barbesino,et al.  Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL‐2) receptor (sIL‐2R) in thyroid diseases , 1992, Clinical endocrinology.

[55]  J. Cerhan,et al.  Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. , 2011, International journal of molecular epidemiology and genetics.

[56]  Pierre Biron,et al.  Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival , 2009, Annals of Hematology.

[57]  Theodore R Holford,et al.  Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.

[58]  M. Čolović,et al.  Predictive value of prognostic indices in patients with follicular lymphomas , 2006, Medical oncology.